These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 2478221

  • 1. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy.
    Gandhi V, Nowak B, Keating MJ, Plunkett W.
    Blood; 1989 Nov 01; 74(6):2070-5. PubMed ID: 2478221
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
    Gandhi V, Plunkett W.
    Cancer Chemother Pharmacol; 1992 Nov 01; 31(1):11-7. PubMed ID: 1458554
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb 01; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 6. Biochemical modulation of arabinosylcytosine for therapy of leukemias.
    Gandhi V, Estey E, Keating MJ, Plunkett W.
    Leuk Lymphoma; 1993 Feb 01; 10 Suppl():109-14. PubMed ID: 8481660
    [Abstract] [Full Text] [Related]

  • 7. Interaction of arabinosyl nucleotides in K562 human leukemia cells.
    Gandhi V, Plunkett W.
    Biochem Pharmacol; 1989 Oct 15; 38(20):3551-8. PubMed ID: 2479383
    [Abstract] [Full Text] [Related]

  • 8. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 15; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 9. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
    Gandhi V, Plunkett W.
    Cancer Res; 1988 Jan 15; 48(2):329-34. PubMed ID: 3335008
    [Abstract] [Full Text] [Related]

  • 10. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF, Huang P, Plunkett W, Gandhi V.
    Clin Cancer Res; 1996 Apr 15; 2(4):653-8. PubMed ID: 9816215
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
    Kemena A, Gandhi V, Shewach DS, Keating M, Plunkett W.
    Cancer Chemother Pharmacol; 1992 Apr 15; 31(3):193-9. PubMed ID: 1464155
    [Abstract] [Full Text] [Related]

  • 12. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
    Gandhi V, Estey E, Keating MJ, Plunkett W.
    J Clin Oncol; 1993 Jan 15; 11(1):116-24. PubMed ID: 8418222
    [Abstract] [Full Text] [Related]

  • 13. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
    Danhauser L, Plunkett W, Liliemark J, Gandhi V, Iacoboni S, Keating M.
    Leukemia; 1987 Sep 15; 1(9):638-43. PubMed ID: 3478543
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.
    Danhauser L, Plunkett W, Keating M, Cabanillas F.
    Cancer Chemother Pharmacol; 1986 Sep 15; 18(2):145-52. PubMed ID: 2431803
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.
    Plunkett W, Liliemark JO, Estey E, Keating MJ.
    Semin Oncol; 1987 Jun 15; 14(2 Suppl 1):159-66. PubMed ID: 3589690
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.